ACHC

Rating neutralAI Memo

Acadia Healthcare

As of 2026-04-29/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q1 2026 release is still the next real thesis check • 2026-04-29

Expected move: +0%

Biggest risk

This remains a monitoring thesis because the actual Q1 2026 earnings release, surprise data, and post-print analyst revisions were not available in the checked evidence as of April 29, 2026. Leadership turnover, the ongoing CEO search, reimbursement sensitivity, and legal-reserve uncertainty mean a weak print or cautious call could quickly undermine the recent stabilization.

Invalidation

Break below $18 or thesis failure.

What would change my mind?

The best near-term support is that Acadia reaffirmed both Q1 and full-year 2026 guidance on April 23, 2026 despite a CFO transition, which suggests no immediate internal reset to expectations [#PR-2026-04-23]. If the pending Q1 print lands within or above the reaffirmed ranges and management shows occupancy and margin traction, the stock could defend the recent rerating.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-29

Base target

$25

p=50%

Bull target

$31

p=25%

Bear target

$18

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Finance-leadership turnover adds another execution credibility test
Bed-add and occupancy execution remains the main path to margin repair
The best near-term support is that Acadia reaffirmed both Q1 and full-year 2026 guidance on April 23, 2026 despite a CFO transition, which suggests no immediate internal reset to expectations [#PR-2026-04-23].

BearKey bullets

Acadia's April 23, 2026 press release still flags reimbursement risk tied to Medicaid financing changes and work or community-engagement requirements in the Medicaid expansion population [#PR-2026-04-23].
CFO turnover is immediate, with Todd Young departing April 30, 2026 and David Duckworth returning as interim CFO while the permanent CEO search remains ongoing [#8-K-2026-04-23] [#PR-2026-04-23].
Cash generation still must cover debt, working-capital needs, and planned 2026 capital expenditures of $255-$280 million, so execution slippage could pressure the balance-sheet narrative [#PR-2026-04-23].

WatchKey bullets

Q1 2026 release is still the next real thesis check

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $25 (p=50%)

Bull/Bear spread: +27% / -26%

Vs latest close: Bull +27% · Base +0% · Bear -26%

Scenario probabilities

Bull Target: $31 (p=25%)Base Target: $25 (p=50%)Bear Target: $18 (p=25%)

Commentary

News tone is mixed but not decisively bearish. The most relevant checked primary source on April 23, 2026 showed a CFO transition alongside guidance reaffirmation, which offsets some immediate concern [#PR-2026-04-23]. However, this scheduled follow-up run lands before checked primary evidence of the actual Q1 2026 earnings release, so earnings surprise data, analyst revision signals, and post-release market reaction are unavailable. Because the anchor price is from April 28, 2026, any move after the planned after-close release on April 29, 2026 is also outside the packet's price baseline. Social coverage was not provided, so conviction should stay moderate rather than upgraded.

As of 2026-04-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Finance-leadership turnover adds another execution credibility test
Bed-add and occupancy execution remains the main path to margin repair

Scenarios

Bull Target (Scenario probability)

$31 / p=25% prob

Base Target (Scenario probability)

$25 / p=50% prob

Bear Target (Scenario probability)

$18 / p=25% prob

Price $24 as of 2026-06-02

Nearest Scenario: Base (∆ 0%)

Targets vs latest close: Bull +27% · Base +0% · Bear -26%

Sentiment & Exposure

News Sentiment (30d)

-0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-04-29
Q1 2026 release is still the next real thesis check
As of April 29, 2026, Acadia had reaffirmed Q1 guidance for revenue of $820-$830 million, adjusted EBITDA of $130-$137 million, and adjusted EPS of $0.25-$0.30, and said it would issue Q1 results after the market close on April 29 with the call on April 30. In the checked primary sources, the earnings release itself was not yet available, so beat/miss data and the initial post-print reaction remain pending rather than proven evidence [#PR-2026-04-23].
Prob 90.00% • Move 9.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Finance-leadership turnover adds another execution credibility test
2026-05-01
Acadia disclosed that CFO Todd Young will leave on April 30, 2026 and former CFO David Duckworth will return as interim CFO effective May 1, 2026, while the search for a permanent CEO remains ongoing. The company also reaffirmed Q1 and full-year 2026 guidance, which limits immediate thesis deterioration, but the leadership churn raises the bar for clean Q1 communication and follow-through [#8-K-2026-04-23] [#PR-2026-04-23].
Prob 76% • Move 6% • Priced-in 68%

Long-term Catalysts

Months to a year

Bed-add and occupancy execution remains the main path to margin repair
2026-12-31
Acadia ended 2025 with 277 behavioral healthcare facilities and over 12,500 beds, after adding 1,089 licensed beds during the year [#10-K-2026-02-27]. Management's 2026 outlook still depends on converting added capacity into occupancy and earnings, with full-year guidance of $3.37-$3.45 billion of revenue and $575-$610 million of adjusted EBITDA, so sustained operating improvement is still a later-2026 execution story rather than a confirmed recovery [#PR-2026-02-25] [#PR-2026-04-23].
Prob 58% • Move 12% • Priced-in 45%

Risks

Acadia's April 23, 2026 press release still flags reimbursement risk tied to Medicaid financing changes and work or community-engagement requirements in the Medicaid expansion population [#PR-2026-04-23].
CFO turnover is immediate, with Todd Young departing April 30, 2026 and David Duckworth returning as interim CFO while the permanent CEO search remains ongoing [#8-K-2026-04-23] [#PR-2026-04-23].
Cash generation still must cover debt, working-capital needs, and planned 2026 capital expenditures of $255-$280 million, so execution slippage could pressure the balance-sheet narrative [#PR-2026-04-23].
Government investigations, litigation, and adverse regulatory actions remain explicit company-stated risks and can drive substantial payments and added regulatory burdens [#PR-2026-04-23].
The Q1 2026 earnings release itself was not yet available in the checked primary sources as of April 29, 2026, leaving surprise, guidance-change, and market-reaction evidence incomplete.

Peers

Symbol	Summary
UHS	Universal Health Services is the closest public operating comp because it also runs behavioral health facilities, making it more relevant than the packet's loose healthcare-services sector matches.
LFST	LifeStance is only a partial comp because it is more outpatient-heavy, but it is still useful for monitoring mental-health demand, reimbursement, and utilization tone against ACHC's inpatient-heavy model.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-29

AI Stock Memo: ACHC - Acadia Healthcare - RankAlpha